MedTrace Logo

Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and Depression

NCT07057024 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-03-06

No results posted yet for this study

Summary

Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are systematically associated with a severe impairment of the overall abilities of patients, which precludes them from functioning adequately in daily life. A large body of literature emphasises the importance of identifying specific markers for these pathologies to prevent or anticipate the emergence of new psychopathological symptoms.

As a result, one of the current research challenges is to develop new, faster, and more reliable tools. Eye movements are physiological signs involving brain areas that control cognitive processes. These same processes could be altered in psychiatric disorders, and these alterations could produce many eye movement abnormalities.

The literature highlights some eye movement abnormalities specific to each targeted pathology. However, to our knowledge, no study has compared eye movement abnormalities in a virtual environment projected in a head-mounted display (HMD).

The investigators hypothesised that an eye tracker connected to an HMD could identify specific eye movement abnormalities of SCZ, BP, and DEP. Recording eye movements specific to these pathologies in pseudo-ecological situations could lead to better identification methods.

Conditions

  • Psychiatric Disorders (Diagnosis)

Interventions

OTHER

Clinical and eye movements

Eye tracking in virtual reality environment: Clinical and psychometric assessment : * Auto-assessment scales : Fagerström Test For Nicotine Dependance (FTND), Annett handedness questionnaire, Alcohol Use Disorders Identification Test (AUDIT), Substance Use Risk Profile Scale (SURPS), Generalized Anxiety Disorder-7 (GAD-7) * Hetero-assessment scales : Young Mania Rating Scale (YMRS), Hamilton Depression Scale (HDRS), Positive And Negative Scale for Schizophrenia (PANSS)

Sponsors & Collaborators

  • Aix Marseille Université

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Hopital Paul Brousse

    collaborator OTHER

  • Etablissement Public de Santé Barthélemy Durand

    lead OTHER

Principal Investigators

  • Eric Artiges · Etablissement Public de Santé Barthélemy Durand

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-12
Primary Completion
2028-02-29
Completion
2029-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07057024 on ClinicalTrials.gov